FDA Launches Elsa 4.0 and Completes HALO Data Platform Consolidation

May.07
FDA Launches Elsa 4.0 and Completes HALO Data Platform Consolidation
The U.S. Food and Drug Administration announced on May 6 that it has advanced its modernization initiative by launching Elsa 4.0, an upgraded internal AI tool, and consolidating more than 40 application and submission data sources, systems and portals into a new platform called HALO. FDA said the integration of HALO and Elsa will allow staff to query data and build workflows without manually uploading documents in each chat.

Key Takeaways

  • FDA announced the launch of Elsa 4.0 on May 6.
  • FDA consolidated more than 40 application and submission data sources, systems and portals into HALO.
  • HALO stands for Harmonized AI & Lifecycle Operations for Data.
  • Elsa 4.0 adds custom agents, document generation, data analysis and visualization, secure web search, voice-to-text and OCR.
  • FDA said Elsa is built in a FedRAMP High secure Google Cloud Platform environment and does not train on input data or data submitted by regulated industry.

2Firsts, May 7, 2026

 

According to the U.S. Food and Drug Administration, the agency announced major steps in its modernization initiative by launching Elsa 4.0 and consolidating multiple data sources, systems and portals.

 

FDA consolidated more than 40 data sources into HALO

 

FDA said Elsa 4.0 is a major upgrade to the agency’s internal AI tool and is available to all FDA staff, including scientific reviewers and investigators.

 

The agency also consolidated more than 40 disparate application and submission data sources, systems and portals across all FDA centers into a new platform called HALO, which stands for Harmonized AI & Lifecycle Operations for Data.

 

Elsa and HALO integration has begun

 

FDA said it has begun integrating HALO and Elsa so that staff can query data and build workflows without manually uploading documents within each chat. 

 

The agency said the HALO consolidation is expected to enable deeper deployment of AI capabilities within agency operations.

 

FDA commissioner said AI tools can reduce staff burden

 

FDA Commissioner Marty Makary said Elsa’s new capabilities position the agency as a leader in deploying AI tools that empower staff. He said removing tedious burdens allows staff to focus more on science and makes workflows more efficient and enjoyable.

 

Chief AI officer said Elsa will become the main entry point to FDA systems and data

 

FDA Chief AI Officer Jeremy Walsh said that with application and submission data sources, systems and portals consolidated into HALO and improvements in Elsa’s capabilities, Elsa will soon become the main entry point into FDA systems and data. 

 

He said FDA staff previously brought data to Elsa, while Elsa now sits on top of the agency’s data.

 

Elsa 1.0 was launched in June 2025

 

FDA said that since launching Elsa 1.0 in June 2025 ahead of schedule and under budget, the agency’s Office of Digital Transformation has continued to roll out improvements and pioneer new use cases with agency reviewers to help streamline operations.

 

Elsa 4.0 adds multiple features

 

According to FDA, new Elsa 4.0 features include custom agents, document generation, quantitative data analysis and visualization, including chart and graph creation, web search through a secure web access feature, voice-to-text dictation, conversion of scanned documents and images into searchable text through OCR, enhanced chat flexibility, and optimized search for key information in large document repositories.

 

FDA said Elsa does not train on input data

 

FDA said Elsa is built within a FedRAMP High secure Google Cloud Platform environment and does not train on input data or any data submitted by regulated industry, safeguarding sensitive research and data handled by FDA staff.

 

FDA said Elsa is not connected to the internet

 

The agency said Elsa’s enhanced search capability allows it to access refreshed secure web data in responses, but it is not connected to the internet.

 

FDA said staff are involved at every stage of the AI work process in Elsa, so that human subject matter experts verify all inputs, analytic processes and output implementation.

 

Image source: FDA

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Imperial Brands Plans Thousands of Job Cuts Across U.S. and Europe in Cost Restructuring
Imperial Brands Plans Thousands of Job Cuts Across U.S. and Europe in Cost Restructuring
According to Reuters, citing Bloomberg News, British tobacco company Imperial Brands PLC plans to cut thousands of jobs across the United States and Europe as part of a cost reduction and organizational restructuring effort. The announcement drew market attention to the company’s shares. The move comes as global tobacco companies continue adjusting their operations amid slower cigarette market growth, changing consumer preferences and the transition toward next-generation nicotine products.
Aug.11
EU ‘TPD3’ Enters Next Phase on Aug. 14 as Fragmented Vape and Nicotine Pouch Rules Push the Single Market Toward Regulatory Overhaul
EU ‘TPD3’ Enters Next Phase on Aug. 14 as Fragmented Vape and Nicotine Pouch Rules Push the Single Market Toward Regulatory Overhaul
A 12-week European Commission consultation on revising the Tobacco Products Directive and Tobacco Advertising Directive is due to close on Aug. 14, 2026. The Commission has identified e-cigarette flavours, disposable vapes, tobacco heating devices, nicotine pouches, nicotine-free e-cigarettes, packaging and digital marketing among areas for possible new EU rules. National regulations already vary significantly across the bloc, a fragmentation the Commission says creates internal-market barriers and distorts competition. No formal revised TPD/TAD legislative text has yet been published, with the Commission currently indicating December 2026 for the legislative initiative.
Aug.14
BAT New Categories Revenue Rises 18% in H1 2026 as Broad Portfolio Offers More Ways to Win—and Lose
BAT New Categories Revenue Rises 18% in H1 2026 as Broad Portfolio Offers More Ways to Win—and Lose
British American Tobacco’s New Category revenue rose 18% at constant rates in the first half of 2026. Nicotine-pouch brand Velo expanded rapidly, while Vuse recovered as U.S. enforcement against illicit e-vapor products strengthened. Heated-tobacco platform glo remained under pressure, and cigarettes continued to provide most of the group’s profit and cash. Compared with PMI and JT, BAT has more routes to growth—but also greater regulatory, investment and execution risks across its broader portfolio.
BAT
Jul.30
Minnesota Sues Loon as State Enforcement Targets U.S. Vape Brand Operators
Minnesota Sues Loon as State Enforcement Targets U.S. Vape Brand Operators
Minnesota Attorney General Keith Ellison sued Maduro Distributors, Inc., doing business as Loon, on July 15, 2026, alleging that the company illegally manufactured, distributed and sold flavored vapes that appeal to minors.
Jul.16
Changing Assumptions in U.S. Cigar Consumption: 2Firsts Interviews Cigar Educator Mechelle Merkerson
Changing Assumptions in U.S. Cigar Consumption: 2Firsts Interviews Cigar Educator Mechelle Merkerson
U.S. premium cigar culture is shifting toward education, broader choice and deeper links to craftsmanship and origin, cigar educator Mechelle Merkerson told 2Firsts. She sees boutique brands, women consumers and production-region experiences making knowledge central to cigar participation. For global brands, retailers and emerging markets such as China, education may help turn curiosity into sustained engagement.
Special Report
Jul.06
2Firsts Interview | InterTabac 2026 Adapts to a More Complex Tobacco and Nicotine Market
2Firsts Interview | InterTabac 2026 Adapts to a More Complex Tobacco and Nicotine Market
As InterTabac 2026 approaches, Sabine Loos, Managing Director of Westfalenhallen Unternehmensgruppe, tells 2Firsts that global tobacco trade fairs are evolving beyond product display. With new nicotine categories, shifting regulation and more complex supply chains reshaping the industry, InterTabac is positioning itself as a platform for market insight, regulatory discussion and global business connection.
Special Report
Jul.02